drugset / Trial / NCT00004852
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
Double-blindTreatment
Summary
The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.
Timeline
- Start
- 1999-09
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamivudine | Other / unclassified | 150 mg | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |
| Background | Efavirenz | Other / unclassified | 600 mg | — |
| Background | Zidovudine | Small molecule | 300 mg | — |